Fei Shao

The paper isolates human monoclonal antibodies against SFTSV Gn, identifies four neutralizing epitope groups, and validates their neutralization through structural analysis.

This paper predicts SARS-CoV-2 RBD evolution using deep mutational scanning to identify broadly neutralizing antibodies effective against existing and prospective variants.

SARS-CoV-2 variant BA.3.2 strongly evades neutralizing antibodies but exhibits low infectivity due to a closed spike conformation, whereas NB.1.8.1 combines high ACE2 affinity with humoral immune escape.

The paper analyzes virological and antigenic traits of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1, finding trade-offs between immune evasion and ACE2 binding efficiency.

This study shows that SARS-CoV-2 variants KP.3.1.1 and XEC have enhanced immune evasion through NTD glycosylation, despite maintaining high ACE2 binding and infectivity.

This study analyzes the humoral immune response to SARS-CoV-2 XBB and JN.1 lineages, showing JN.1 elicits superior neutralization and highlights the need for JN.1-based vaccine boosters.

The paper investigates how Omicron-specific naive B cell maturation after breakthrough infection alleviates immune imprinting from inactivated SARS-CoV-2 vaccines.

This study identifies ultra-potent Omicron-specific antibodies targeting the N1/N2 loop of the Spike NTD, which neutralize SARS-CoV-2 by competing with ACE2 and blocking S1 shedding, but are evaded by BA.2.86 and BA.2.87.1 sublineages.

This study investigates how N354 glycosylation in the SARS-CoV-2 spike protein affects viral fitness and human adaptation through multiple mechanisms.

This study assesses the antigenic properties and immune evasion of the SARS-CoV-2 variant BA.2.87.1, finding it less resistant to neutralizing antibodies than JN.1 but with compensatory deletions in the NTD.

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

The paper shows JN.1 outcompetes BA.2.86 and other variants by evading antibodies more effectively, despite reduced ACE2 binding.